Company Overview
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
Why Investors Should Care
Net profit has compounded at 24.4% per year over the last five years.
Operating margin of 19.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.26.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $5.94B (+8.7% YoY); net profit $782.30M.
- Trailing 12 Months Year-on-year growth — revenue +7.3%, earnings +14.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.6%, profit CAGR 24.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.55% |
| 1 Year: | 7.30% |
Compounded Profit Growth
| 5 Years: | 24.36% |
| 1 Year: | 14.00% |
Stock Price Performance
| 1 Year: | -6.45% |
| 6 Months: | -1.98% |
| 3 Months: | +6.40% |
| 1 Month: | -2.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.10 · Neutral
P/E of 27.46 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 24.4% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STE STERIS plc SPXR3KPHARMA | 224.59 | 27.46 | $21.89B | 1.11% | 11.49% | 11.39% | 9.55% | 24.36% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 607.96M | 661.90M | 715.97M | 638.76M | 678.96M | 696.24M | 768.21M | 696.80M | 736.84M | 774.26M | 822.99M | 668.93M | 756.13M | 808.92M | 873.53M | 968.42M | 1.20B | 1.21B | 1.21B | 1.05B | 1.09B | 1.11B | 1.28B | 1.18B | 1.24B | 1.30B | 1.42B | 1.28B | 1.33B | 1.37B | 1.39B | 1.46B | 1.50B | 1.49B |
| Gross Profit | 255.77M | 278.22M | 292.37M | 269.05M | 284.66M | 287.00M | 334.72M | 306.89M | 318.67M | 331.35M | 363.09M | 287.38M | 330.04M | 345.86M | 379.82M | 426.28M | 480.34M | 538.11M | 571.62M | 473.82M | 482.31M | 478.19M | 546.40M | 529.00M | 546.23M | 560.03M | 582.90M | 572.40M | 578.80M | 610.30M | 628.00M | 645.90M | 655.50M | 684.20M |
| Operating Income | - | - | - | 94.42M | 106.58M | 69.58M | - | 110.09M | 126.73M | 142.39M | - | 115.82M | 141.26M | 147.03M | - | 14.32M | 116.50M | 202.93M | - | 158.40M | -306.42M | 190.80M | - | 197.76M | 191.55M | 226.47M | - | 185.50M | 219.70M | 245.30M | 246.00M | 265.80M | 273.20M | 285.80M |
| Net Income | 58.08M | 94.78M | 73.60M | 69.99M | 77.46M | 47.86M | 108.75M | 85.37M | 94.77M | 104.93M | 122.59M | 89.60M | 105.86M | 114.50M | 87.44M | -21.81M | 69.81M | 143.62M | 52.26M | 111.26M | -315.29M | 123.83M | 187.22M | 123.55M | 115.32M | 140.74M | -1.38M | 145.40M | 150.00M | 173.50M | 177.40M | 191.90M | 192.90M | 200.10M |
| Diluted EPS | 0.68 | 1.11 | 0.86 | 0.82 | 0.91 | 0.56 | 1.27 | 1.00 | 1.11 | 1.23 | 1.43 | 1.05 | 1.23 | 1.33 | 1.02 | -0.24 | 0.69 | 1.42 | 0.52 | 1.10 | -3.15 | 1.24 | 1.88 | 1.25 | 1.16 | 1.42 | -0.01 | 1.46 | 1.51 | 1.75 | 1.79 | 1.94 | 1.96 | - |
| R&D Expense | - | - | - | 16.22M | 15.77M | 15.17M | - | 15.59M | 16.25M | 16.49M | - | 16.23M | 16.14M | 16.44M | - | 18.19M | 18.83M | 24.82M | - | 24.75M | 24.93M | 25.51M | - | 24.69M | 26.27M | 25.25M | - | 25.60M | 27.00M | 27.40M | 26.40M | 28.20M | 29.50M | 28.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.61B | 2.62B | 2.78B | 3.03B | 3.11B | 4.22B | 4.54B | 5.14B | 5.46B | 5.94B |
| Gross Profit | 1.03B | 1.09B | 1.17B | 1.32B | 1.34B | 1.88B | 1.98B | 2.22B | 2.40B | 2.63B |
| Operating Income | 226.21M | 399.88M | 411.02M | 537.05M | 548.37M | 477.81M | 791.10M | 836.10M | 866.60M | 1.10B |
| Net Income | 109.97M | 290.92M | 303.72M | 407.66M | 397.40M | 243.89M | 107.03M | 378.20M | 614.60M | 782.30M |
| Diluted EPS | 1.28 | 3.39 | 3.55 | 4.76 | 4.63 | 2.48 | 1.07 | 3.81 | 6.20 | 7.93 |
| R&D Expense | 59.40M | 60.78M | 63.04M | 65.55M | 66.33M | 86.66M | 98.48M | 103.70M | 107.60M | 112.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.20B | 5.07B | 5.44B | 6.57B | 11.42B | 10.82B | 11.06B | 10.15B | 10.74B |
| Total Equity | 3.04B | 2.81B | 3.21B | 3.18B | 3.41B | 3.88B | 6.53B | 6.08B | 6.30B | 6.60B | 7.18B |
| Cash & Equivalents | 248.84M | 282.92M | 201.53M | 220.63M | 319.58M | 220.53M | - | - | - | - | - |
| Long Term Debt | - | - | 1.32B | 1.18B | 1.15B | 1.65B | 2.95B | 3.02B | 3.12B | 1.92B | 1.81B |
| Total Liabilities | - | - | 1.98B | 1.89B | 2.02B | 2.68B | 4.88B | 4.73B | 4.75B | 3.53B | 3.54B |
| Current Liabilities | - | - | 398.46M | 465.20M | 503.61M | 577.92M | 922.22M | 861.84M | 931.13M | 1.02B | 1.15B |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 424.09M | 457.63M | 539.50M | 590.56M | 689.64M | 684.81M | 756.95M | 973.30M | 1.15B | 1.34B |
| Investing Cash Flow | -104.25M | -203.83M | -213.22M | -319.74M | -1.15B | -666.56M | -383.33M | -887.40M | 388.80M | -512.50M |
| Financing Cash Flow | -267.10M | -356.18M | -294.79M | -163.15M | 345.62M | 115.83M | -498.72M | -85.20M | -1.57B | -568.20M |
| Capital Expenditure | -172.90M | -165.46M | -189.72M | -214.52M | -239.26M | -287.56M | -361.97M | -360.30M | -370.10M | -369.00M |
| Free Cash Flow | 251.19M | 292.18M | 349.79M | 376.04M | 450.38M | 397.25M | 394.98M | 613.00M | 778.00M | 972.40M |
| Share Buybacks | 97.51M | 65.48M | 81.49M | 51.24M | 14.65M | 55.78M | 308.56M | 11.80M | 211.30M | 235.50M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 39.3% | 41.7% | 42.2% | 43.6% | 43.2% | 44.6% | 43.7% | 43.2% | 44.0% | 44.2% |
| Operating Margin % | 8.7% | 15.3% | 14.8% | 17.7% | 17.6% | 11.3% | 17.4% | 16.3% | 15.9% | 18.6% |
| Net Margin % | 4.2% | 11.1% | 10.9% | 13.5% | 12.8% | 5.8% | 2.4% | 7.4% | 11.3% | 13.2% |
| ROE % | 3.9% | 9.1% | 9.6% | 12.0% | 10.2% | 3.7% | 1.8% | 6.0% | 9.3% | 10.9% |
| ROCE % | - | 8.3% | 8.9% | 10.9% | 9.1% | 4.6% | 7.9% | 8.3% | 9.5% | 11.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.05% | 8.82M | $2.06B |
| 2 | Vanguard Capital Management LLC | 6.57% | 6.41M | $1.50B |
| 3 | State Street Corporation | 5.20% | 5.07M | $1.19B |
| 4 | Vanguard Portfolio Management LLC | 5.13% | 5.00M | $1.17B |
| 5 | Morgan Stanley | 4.05% | 3.95M | $923.45M |
| 6 | Massachusetts Financial Services Co. | 3.90% | 3.80M | $888.62M |
| 7 | Wellington Management Group, LLP | 3.59% | 3.50M | $818.91M |
| 8 | Orbis Allan Gray Ltd | 2.75% | 2.68M | $626.00M |
| 9 | Geode Capital Management, LLC | 2.68% | 2.62M | $611.53M |
| 10 | Generation Investment Management LLP | 2.34% | 2.28M | $533.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STE
STERIS (STE) Stock Looks Reasonable On Earnings With Cash Flow Slightly Stretched - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNOWppalZpYTBBcWx3QzB0cXkyc3kyelNLbnozdDVybXRtOFVPUDVJbE52LVlxemtvWERxTUZHeXV3WG1mSWFtN3U3QjE0SEtVcFZEWmM4SWhGZFJLNUpLMlJnaVpVTnRCbWpvMy0zV1F4RjNQTjhHZzItSFlUMjh1XzJVc0N0bnJZblJYYW…
STERIS plc (STE) Stock Analysis: Navigating a 17% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSmk3dFltOUVxUFFpWFU4aWw3ekR2RnIzdGJjOW5mUjdDZmR2Y0RxTW8tTXBYQnVwNzlKemJDaTNiSjYwNkxUaXhfUkRhRTFROXk2UGN2eV9oQ1daM3ZEQWRISEt4YU9WcDV6TW50YWFMZEdjRGpObjRrY1Y1Ym1naEk0VjhEWGFReEp6Yk…
Rep. Jared Moskowitz Sells Shares of STERIS plc (NYSE:STE) - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQVDdEVnJ3Mlg1OXN3VmVJV2xKNDlPTTZ1VV9qLXNHNGxkLU9ULXpPRHNfOFFrTkZJbldpUzdweEU4TjY4QjFYZnFFcEMwMnNqY3R0Xy1lMnlCS3gwVXA1QnJYa3ZBdDlnamk5anNkMk9Qb1EtTUlvay0tckpYZmtuLUtETTJ5b2xseWhOM2…
Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQZF9wRkwtUHMzd2pIb2NvUlBZMmIwb3RZOGM3TEdSYXBOcFdPQm9hb2FOc2N5c25XUDdmdm03QkkzT0YtbGNScVNGai0yWWhWa1lDOS03MVd0RXEzTHE2VWdnMHp6MkNSblpJWEQtUVQ5NFhoWU85LXN4VzdTX2tQcEExNzEtRDUxWVJqZQ…
How Will Steris Stock React To Its Upcoming Earnings? - Trefis
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNS1FYeXhjMVNiTDUxek1NdlVsM3l0SjIwYTNtSTBhOHN0cVJSOUV5ZC0tcGVwVzBUcmliUmFRd0oxc2R5bG1Fa2FXSWkwUEFQT3VzTHk1RVFSVDJ5N3pqbllRbURRUXh2S2pzR09GRHAyQTRKSGRLMEVzenNFbEJBb2hDVnRzMl84TkQxSF…
STERIS plc (STE) Stock Rises on Q4 2026 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQYWk3X1NWSFZoVmVKb0NQdFJMVUttbVIxNUxuUzRiaVBoUkNNU1MzbkNJZVk3UU56UXpNRlBnSkVEcEt0VzViejdwSUdjb1plNy1PZzVUQkNGcUw5cms2NzJSampfY0lmNFJqbjhFaWJGRE8xSlYyODVVVkpoeXdfSzJoVmhncmVIRXo4bU…
STE — Frequently Asked Questions
What is the current share price of STERIS plc (STE)?
As of 2026-09-07 16:24 PDT, STERIS plc (STE) trades at $224.59 on NYSE. Its 52-week range is $198.79 to $266.36.
What is the market capitalisation of STE?
STERIS plc (STE) has a market capitalisation of $21.89B on NYSE.
What is the P/E ratio of STE?
STE trades at a trailing price-to-earnings (P/E) ratio of 27.46. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.23.
Does STE pay a dividend?
STERIS plc (STE) currently offers a dividend yield of 1.11%.
What is the return on equity (ROE) of STE?
STE has a return on equity (ROE) of 11.39%. Its return on capital employed (ROCE) is 11.49%.
Is STE a good stock to buy?
This page provides a data-driven analysis of STERIS plc (STE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.